Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season
Most Cited Paper
in Neonatal Respiratory Health Research
18 Months Post-Publication
Class of 2026
“Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026/
Topics
nirsevimab · Respiratory syncytial virus (RSV) · RSV bronchiolitis · Monoclonal antibody · universal prophylaxis · Infants · Infants under 1 year · Valle d'Aosta · 2023–2024 epidemic season · Hospitalization prevention · Passive immunization · RSV prophylaxis · prophylaxis adherence · real-world effectiveness
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Neonatal Respiratory Health Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026. Accessed 2026-07-22. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459